Pancreatic Endocrine Tumors—c-erb B2 (Her-2/neu), bcl-2, and p-53 Immunohistochemical Testing and Their Value in Assessing Prognosis

IntroductionIn an attempt to identify better prognostic factors, and the genetic basis of pancreatic endocrine tumors (PETs), we evaluated immunohistochemical reactivity for c-erb B2 (Her-2/neu), bcl-2, and p53. Methods and MaterialsTwo pathologists reviewed hematoxylin and eosin slides and immunohistochemical stains from 28 cases, 27 tumors and 1 nesidioblastosis. Using WHO criteria for malignancy (presence of local or lymphovascular invasion and/or metastases), cases were divided into malignant (20 cases) and benign or uncertain (8 cases). Nuclear staining in >1% of cells was considered positive for p53 and bcl-2, whereas membranous staining was considered positive for c-erb B2 (Her-2/neu). ResultsAll cases were nonimmunoreactive with anti-c-erb B2 (Her-2/neu), but focal granular or diffuse cytoplasmic staining was seen in occasional neoplasms. One malignant PET showed reactivity with anti-p53, whereas all others were negative. bcl-2 reactivity was identified in 15/28 cases: 9/20 malignant PETs and 6/8 others were positive. Conclusionsc-erb B2 (Her-2/neu) and p53 are not useful prognostic factors in PET. c-erb B2 (Her-2/neu) staining must be carefully evaluated to avoid the misinterpretation of artifactual/background staining. bcl-2 is occasionally expressed in PET, but the significance of this finding is still to be determined.

[1]  L. Piro.  Apoptosis, Bcl-2 antisense, and cancer therapy. , 2004, Oncology.

[2]  C. Morrison,et al.  C-erb B2 (Her2/ neu) Is Neither Overexpressed nor Amplified in Hepatic Neoplasms , 2002, Applied immunohistochemistry & molecular morphology : AIMM.

[3]  M. Raffeld,et al.  Her-2/neu expression and gene amplification in gastrinomas: correlations with tumor biology, growth, and aggressiveness. , 2002, Cancer research.

[4]  L. Gullo,et al.  Carcinoid of the Pancreas , 2002, Pancreatology.

[5]  M. Wick,et al.  Pancreatic neuroendocrine neoplasms: a current summary of diagnostic, prognostic, and differential diagnostic information. , 2001, American journal of clinical pathology.

[6]  R. DeLellis.  The neuroendocrine system and its tumors: an overview. , 2001, American journal of clinical pathology.

[7]  M. Heymann,et al.  Prognostic and immunohistochemical validation of the Capella classification of pancreatic neuroendocrine tumours: an analysis of 82 sporadic cases , 2000, Histopathology.

[8]  S. Jiang,et al.  The significance of frequent and independent p53 and bcl-2 expression in large-cell neuroendocrine carcinomas of the lung. , 1999, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[9]  A. Gobl,et al.  Interferon-alpha induces bcl-2 proto-oncogene in patients with neuroendocrine gut tumor responding to its antitumor action. , 1997, Anticancer research.

[10]  K. Buchanan,et al.  Oncogene expression in gastroenteropancreatic neuroendocrine tumors , 1997, Cancer.

[11]  B. Evers,et al.  Amplification of the HER-2/neu protooncogene in human endocrine tumors. , 1992, Surgery.

[12]  S. Bloom,et al.  Morphologic patterns and diagnostic criteria of VIP‐producing endocrine tumors. A histologic, histochemical, ultrastructural, and biochemical study of 32 cases , 1983, Cancer.

[13]  Gilmore Hr,et al.  Armed Forces Institute of Pathology. , 1968, Oral surgery, oral medicine, and oral pathology.

[14]  K. T. Steigelman.  Tumors of the pancreas. , 1951, The Journal of the American Osteopathic Association.